<DOC>
	<DOC>NCT00062647</DOC>
	<brief_summary>The purpose of this study is to determine whether telavancin (TD-6424, ARBELIC) can be safety administered to patients with bloodstream infections and whether telavancin is effective in treating these infections.</brief_summary>
	<brief_title>Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia</brief_title>
	<detailed_description />
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Bacteremia</mesh_term>
	<mesh_term>Gram-Positive Bacterial Infections</mesh_term>
	<mesh_term>Oxacillin</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Telavancin</mesh_term>
	<mesh_term>Nafcillin</mesh_term>
	<mesh_term>Cloxacillin</mesh_term>
	<criteria>Inclusion Criteria Documented S. aureus bacteremia Exclusion Criteria Patients who had received or would have received more than 72 hours of potentially effective systemic antistaphylococcal therapy within 7 days prior to randomization. The following agents were considered potentially effective antistaphylococcal therapy: antistaphylococcal penicillins (including nafcillin, oxacillin, or cloxacillin), cephalosporins, fluoroquinolones, glycopeptides (including vancomycin and teicoplanin) and linezolid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>